MetaCap

Lisata Therapeutics (LSTA) vs Matinas Biopharma (MTNB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Matinas Biopharma is the larger company by market cap ($890,711 vs $647,451), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LSTA-23.17%MTNB-71.12%
+13%-31%-75%
Oct 7, 20261 yearNov 20, 2026
LSTA-15.20%MTNB-72.13%
+18%-29%-76%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LSTA versus MTNB key metrics
MetricLSTAMTNB
Share price$0.8989$0.7999
Market cap$647.45K$890.71K
1-day change-1.22%-1.26%
YTD return-51.67%—
1-year return-54.14%—
5-year return-93.89%—
EPS (TTM)$-28.20$-17.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$170.00K—
Revenue growth (YoY)-83.00%—
Net income (latest FY)$-16.59M$-10.35M
Operating margin-10711.18%—
Net margin-9756.47%—
52-week high$76.05$14.63
52-week low$0.85$0.75
Distance from 52-week high-98.82%-94.53%
Analyst consensusnone—
Average volume13.46K80.86K
Shares outstanding720.27K1.11M
Employees212
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Lisata Therapeutics

LSTA stock →

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Matinas Biopharma

MTNB stock →

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

LSTA vs MTNB FAQ

Which is bigger, Lisata Therapeutics or Matinas Biopharma?

Matinas Biopharma (MTNB) is larger, with a market capitalization of $890.71K compared with $647.45K for Lisata Therapeutics (LSTA).

Are Lisata Therapeutics and Matinas Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons